Corteva, Inc. CTVA
Verdict: Sell. Fair value $63.38 against a price of $67.85 on 6 Jan 2026, 7% below the price.
In plain words
The case for: Narrow competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. Revenue has declined for two consecutive years, from a peak of $17.45B in 2022 to $17.23B in 2023.... Operating Cash Flow was extremely weak in 2022 at $0.87B, resulting in an OCF/NI ratio of only....
Main risks
- Declining Revenue and Profitability: Annual revenue has declined for two consecutive years from its 2022 peak, and net income has fallen sharply from $1.76B in 2021 to $0.91B in 2024, indicating significant margin compression.
- Poor Return on Capital: ROE (3.8%) and ROIC (6.0%) are extremely low for a company of this scale, suggesting inefficient use of its large asset and equity base. These returns are likely below the company's cost of capital.
- Erratic Cash Flow History: While TTM FCF is strong, the annual figures show high volatility, dropping from $2.15B in 2021 to just $0.27B in 2022 before recovering. This inconsistency makes it difficult to project future cash generation with confidence.
- Revenue has declined for two consecutive years, from a peak of $17.45B in 2022 to $17.23B in 2023...
- Operating Cash Flow was extremely weak in 2022 at $0.87B, resulting in an OCF/NI ratio of only...
- Intense competitive environment